OSAKA -- Shionogi will start clinical trials for a COVID-19 nasal spray vaccine in fiscal 2022, the Japanese pharmaceutical company announced Tuesday, paving the way for an inoculation method that would benefit countries lacking medical staff.
COVID vaccines
COVID nasal spray vaccine set to enter clinical trial in Japan
Shionogi's inoculation method to help emerging nations lacking medical staff
Read Next
.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on COVID vaccines
